Weiss Ratings Reaffirms "Hold (C-)" Rating for Zoetis (NYSE:ZTS)

Key Points

• Weiss Ratings has reaffirmed a "Hold (C-)" rating for Zoetis (NYSE:ZTS), indicating a cautious stance on the stock amidst fluctuating analyst ratings from other brokerages.
• Zoetis reported earnings of $1.76 per share, exceeding analysts' expectations and showcasing a 4.2% increase in quarterly revenue compared to the prior year.
• The stock of Zoetis is currently trading at $143.73, with an average target price of $200.88, reflecting a consensus rating of "Moderate Buy" among analysts.

Zoetis (NYSE:ZTS - Get Free Report)'s stock had its "hold (c-)" rating restated by analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Several other brokerages have also recently commented on ZTS. Argus restated a "buy" rating and set a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and reduced their target price for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Piper Sandler increased their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Finally, Leerink Partnrs cut shares of Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Five investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $200.88.

Zoetis Stock Up 0.7%

Shares of Zoetis stock traded up $0.96 on Wednesday, hitting $143.73. The company had a trading volume of 1,460,618 shares, compared to its average volume of 3,034,967. The firm has a market capitalization of $63.70 billion, a P/E ratio of 24.78, a P/E/G ratio of 2.33 and a beta of 0.90. Zoetis has a twelve month low of $139.34 and a twelve month high of $196.55. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The stock has a 50-day moving average of $149.52 and a 200-day moving average of $154.82.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business's quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts predict that Zoetis will post 6.07 earnings per share for the current year.

Institutional Trading of Zoetis

A number of large investors have recently added to or reduced their stakes in ZTS. Nova Wealth Management Inc. acquired a new stake in Zoetis in the first quarter valued at $25,000. 1248 Management LLC bought a new position in shares of Zoetis in the first quarter valued at about $27,000. Saudi Central Bank bought a new position in shares of Zoetis in the first quarter valued at about $29,000. Cornerstone Planning Group LLC raised its position in shares of Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after purchasing an additional 88 shares during the period. Finally, REAP Financial Group LLC raised its position in shares of Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company's stock valued at $31,000 after purchasing an additional 131 shares during the period. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.